Tiziana Life Sciences to File Alzheimer’s IND for Intranasal Foralumab in Q2 2023

 

• Application for $3M of non-dilutive funding for Phase 2a Alzheimer’s trial will be submitted in Q2 2023
• Tiziana guided by FDA Type “B” meeting comments on its scheduled Q2 2023 intranasal foralumab Alzheimer’s IND filing
• Alzheimer’s patients will be administered 3-months of intranasal foralumab to study effects on neuroinflammation caused microglia activation

https://www.biospace.com/article/releases/tiziana-life-sciences-to-file-alzheimer-s-ind-for-intranasal-foralumab-in-q2-2023/